Index

a
abuse/dependence of medication 245
acamprosate 220
acetylcholine neuron loss 292
acetylcholinesterase inhibitor (AChEI) 7, 292–293, 303
actigraphy 178
activities of daily living (ADLs) 293
add-ons/augmented/adjunctive treatments 118–120
adherence/compliance
  medication adherence 67, 71, 76, 347
  behavioral adherence to treatment plan 68–70, 205–206, 221, 257
adjustment disorder, with depression 85–106
agitation 220
agoraphobia 113, 116
aggression 250–252, 257, 258–259, 260, 264, 268, 303
algorithm 43, 64, 72, 179, 256
alprazolam 96, 116
Alzheimer’s disease (AD) 7, 292–294
amantadine 119
amineptine 89
aminergic neurotransmitter systems 217
amitriptyline 92, 139, 174
amobarbital 339, 346
analgesics 202
anergia 340
anger control skills training (ACST) 7
anhedonia 340
antihistamines 175
anticholinergic side-effects 109
antidepressant medication 42, 48, 53, 95, 141, 202, 286
antiobesity agents (orlistat, D-fenfluramine, locaserin) 220
antipsychotic medication 96, 119, 139, 259, 261, 303
antisocial personality disorder 259
anxiety disorders 4, 5, 107–124
anxiolytic 95, 109, 110
aripiprazole 5, 7, 54, 141, 260, 287
atenolol 114
attention deficit hyperactivity disorder (ADHD) 222, 243–251, 343
atypical (second generation) antipsychotic 175, 220
augmentation of medication 53
automoxetine 220, 246, 249, 257
aversion therapy 347
aversive agents 329, 335

b
barbiturate 169
bariatric surgery 219
Beck, Aaron 46
Beck Depression Inventory (BDI) 40, 51, 92
behavioral analysis 144
behavioral and psychological symptoms of dementia (BPSD) 300–301, 303–306
behavioral disturbances concomitant with dementia 303–307
behavioral economics 331
behavioral therapy 46, 244, 247, 251, 258
behavioral parent training (BPT) 7
behavior modification 249, 267
beta-blocker 6
biofeedback 177, 197, 204–205
biological model 89
biopsychosocial paradigm 326
biopsychosocial treatment 1–15
bipolar disorder I & II 61–78
depression 71–73
mania 63–71
black box warning from FDA 43, 97, 100, 174, 301, 304
Bleuler, Eugen 19
blood cell count 66
bona fide psychotherapy 48–49
borderline personality disorder 6, 7, 8, 137–165, 227
brief psychodynamic therapy (BPD), 288, 290
brief psychotic disorder 18
bromide salts 169
buprenorphine 203–204, 335
buproprion 5, 42–43, 99, 222
buspirone 109

C

cannabidiol (CBD), 202
catatonia 5, 19
catecholamines 87
carbamazepine 5, 66, 139
childhood/adolescent disorders 243–284
chlordiazepoxide 169
circadian process 172
citalopram 44–45, 52, 99, 298
classical (respondent) conditioning 325, 327, 329, 332
Clinical Antipsychotic Trail of Intervention Effectiveness—Alzheimer’s Disease (CATIE-AD), 301
clinical psychopharmacology 8, 86
clozapine 141
combined therapy (medication/psychotherapy) 2, 5–8
anxiety disorders 110, 121
generalized anxiety disorder (GAD) 111–112
obsessive-compulsive disorder (OCD) 120
panic disorder 116
posttraumatic stress disorder (PTSD) 118
social anxiety disorder 114
specific phobias 113
borderline personality disorder 153
childhood/adolescent disorders
attention deficit hyperactivity disorder (ADHD) 248–249
conduct disorder 266–269
oppositional defiant disorder (ODD) 255–256
eating disorders 226, 227
elderly
behavioral disturbances concomitant with dementia 307
cognitive deficits of dementia 297
depression concomitant with dementia 300
late-life depression 290–291
psychotic symptoms concomitant with dementia 302
insomnia 179–180
mood disorders
adjustment disorder with depression 100
bipolar disorder 77–78
dysthymic disorder 90–93
major depressive disorder 49–53
pain 196, 210
psychosis 21, 30
Commonality (among treatments) 2
common factor 49, 110, 153, 330, 331, 339
Co-morbid conditions associated with dementia 297
co-morbidity 7
attention deficit hyperactivity disorder (ADHD) 249–251
conduct disorder 268
oppositional defiant disorder (ODD) 256–258
computer tomography (CT) 20
conditioned stimulus (CS) 328, 329
conditioning 328
conduct disorder 258–269
parent training programs 263–264
Brief Strategic Family Therapy (BSFT) 265
Functional Family Therapy (FFT) 265
Multidimensional Treatment Foster Care (MTFC) 265
Multisystemic Therapy (MST) 264–265
Parent-child interaction therapy (PCIT) 264
Parent Management Training (PMT) 263
Problem-Solving Skills Training (PSST) 263
Connor’s Rating Scales 262
consult-liaison psychiatry 95
contextual conditioning 339
contingency management 247
contraindicated 2
counseling model 146
coordinated integrated therapy, CBP examples
anxiety 338–340
depression 340–341
psychosis 341–342
other syndromes 343–347
cortisol levels 217
counterconditioning 330, 345
cover covert learning 328
cyclobenzaprine 202
cytokines 87
d
Daily Report Card (DRC) 247
D-cycloserine 109, 113, 115, 120
degree of confidence 4
delusion(s) 17, 220, 300, 302
delusional disorder 18
dementia 291–297
with Lewy bodies (DLB) 292, 295
Depression Awareness, Recognition, and Treatment (DART) Program, xi
depression concomitant with dementia 297–300
desipramine 92, 290
desvenlafaxine 222
dextroamphetamine 223, 267
Diagnostic and Statistical Manual (DSM) 17, 41, 61, 85–86, 94, 107, 137, 167, 217, 243, 291
dialectical behavioral therapy (DBT) 6, 7, 143–145, 147, 218
diazepam 346
differential-reinforcement-of-low-rate (DRL) 341
diphenhydramine 175
discontinuation (syndrome) of medication 9, 111
disruptive disorders 243–284
disulfiram 335, 345
donepezil 292–294, 301, 336
dopamine 42, 244
  low dopamine hypothesis 222
dopamine norepinephrine reuptake inhibitor (DNRI) 7
double depression 86, 89, 91–92, 221
down regulation of receptors 197
doxepin 174, 287
drop out rate 43–48, 89, 98, 111–113, 116, 117, 120, 143–144, 199, 266, 286, 293, 294, 298, 304
drug contract 201
drugs, as reinforcers 331
duloxetine 45, 99, 222
duration of untreated psychosis (DUP) 22, 25, 30, 33
Dutch Practice Guidelines for Managing Adjustment Disorders 99
Dysfunctional Attitude Scale (DAS) 92
Dysfunctional Beliefs about Sleep scale (DBAS) 178
dysthymia 85–106
eating disorder 4, 7, 9, 217–242
  anorexia nervosa 7, 217
  binge eating disorder (BED) 7, 218–219
  bulimia nervosa (BN) 7, 217
effect size 49–50, 92, 110, 151, 173, 179, 207, 247, 289–290
ego-dystonic cognitive rumination 223
Einstein Aging Study 292
elder population
  late-life depression 7
cognitive deficits of dementia 7
depression concomitant with dementia 7
psychotic symptoms concomitant dementia 7, 9
behavioral symptoms concomitant with dementia 7
electroconvulsive therapy (ECT) 5, 63, 67, 72
endorphin 183
Epidemiological Catchment Area Study 94
epinephrine 339
escitalopram 45–46, 98–99
euphoria 333, 335
evidence-based 1–15
exclusion criteria 40
executive dysfunction 288, 290
exercise, physical 176, 208, 299
experimental design 1, 224
exposure therapy 110, 112, 119, 338
flooding/implosion 109, 116, 338
desensitization 109, 338
extinction 113, 330, 339, 345
Eyberg Child Behavior Inventory (ECBI) 253
eye-movement desensitization and reprocessing (EMDR) 117
family focused therapy (FFT) 63, 70, 73, 76
family therapy 5, 27, 218, 244
fentanyl 203
fibromyalgia 175, 205
first-episode psychosis (FEP) 26–28, 33
first-generation antipsychotic medication 66
first-line treatment recommendations 4, 5
fluoxetine 7, 42, 91, 98–99, 222, 267
fluvoxamine 99, 115
Fordyce, Wilbert 196, 325
g

gabapentin 175
galanatamine 292–293
galanin 168
gamma-aminobutyric acid (GABA) 168
generalized anxiety disorder (GAD) 110–112
Generalized Anxiety Disorder-7 (GAD-7) 101
geriatric disorders 285–324
global assessment of functioning (GAF) 22, 28
 glutamate 110
gold standard 39, 248, 252
Good psychiatric management/general psychiatric management (GPM) 146
group therapy 6, 9, 114–116, 120, 143, 152, 178, 219, 226, 300
guanfacine 246

h

hallucinations 17, 300, 302
haloperidol 66, 139, 304
Hamilton Rating Scale for Depression (HAM-D) 40, 44, 48, 90
headache 205
head-to-head (comparisons) 2, 40, 44, 47, 48, 66, 72, 111, 116, 153, 246, 298
histamine 175
HIV 175, 208
Hopkins Symptom Checklist (HSCL) 51
5-HT1A receptor 43
hydrocodone 193
hydroxyzine 110
hyperarousal 168
hypomania 62
hypnotism 200

i

iatrogenic outcomes 8, 46
imipramine 108, 115, 338–339
impulsivity/behavioral dyscontrol 141–142, 243–244

independent variable 2
inflammatory factors
C-reactive protein, interleukin-6, tumor-necrosis factor-α 86
insomnia 6, 8, 167–192, 199
Insomnia Severity Index (ISI) 177
Instrumental conditioning see operant (instrumental) conditioning
integrated neurocognitive therapy (INT) 22
integration 1–15
biopsychosocial 21–25, 110, 179–180
of therapies 21
intensive sleep retraining (ISR) 178
International Classification of Sleep Disorders (ICSD) 167
International Statistical Classification of Diseases (ICD) 17, 41, 61, 167
Interpersonal and Social Rhythm Therapy (IPSRT) 73, 76
interpersonal therapy (IPT) 5, 46, 48, 91–92, 218, 225–226, 288
intrathecal opioid pump 202

k

Kava-Kava 110
Kraepelin, Emil 19
Kahlbaum, Karl Ludwig 85

l

Lambeth Early Onset (LEO) 23
lamotrigine 72, 74, 142
Late-life depression (LLD) 285–291
Learned helplessness 327
learning disabilities 250
learning theory 327
levomilnacipran 220
limbic system 331
lisdexamfetamine 220, 223
lithium 5, 63, 66, 72, 74, 142, 251
liver enzymes 66
Longitudinal Interval Follow-up Evaluation 90
lorazepam 96
lurasidone 72
magnetic resonance imaging (MRI) 285
major depressive disorders 39–55
manic-depression 61
Maudsley method/model 218, 226
Maudsley Obsessive-Compulsive Inventory 119
Medical marijuana 202
medication adherence/compliance see adherence/compliance
medication-induced psychiatric symptoms
  bipolar disorder 72
  psychotic disorder 19
Medication rebound 205
melancholia 61, 85
melatonin 168, 172–173
memantine 7, 293, 305, 336
mentalization-based therapy (MBT) 6, 145
meprobamate 108
mesolimbic dopaminergic pathway 330, 332
mesolimbic reward system 333 see also pleasure center
meta-analyses 1–3, 25–27, 48
metabolic measures
  triglycerides, high-density lipoprotein (HDL), fasting glucose 87
metabolic syndrome 66
methadone 203–204
methylphenidate 220, 287
milnacipran 99
mindfulness 111, 118
Mini-Mental State Exam (MMSE) 295
mirtazapine 44, 99, 174
 moclobemide 92, 298
molindone 259
Monoamine oxidase inhibitor (MAO-I) 42, 88, 117
monoamines 42
monotherapy/stand-alone therapy 6, 9, 50–52, 110, 112, 115, 118, 120, 249
Montgomery–Asberg Depression Scale (MADRS) 44
mood disorder 4, 39–59, 61–84, 85–106
mood stabilizer/anticonvulsant 5, 66, 72, 141, 175, 202, 223, 260
motivation 330
motivational center 331
morphine 193
multidisciplinary approach 6
multimodal treatment 1, 2, 227, 247–249, 255, 269
Multimodal Treatment Study of Children with ADHD (MTA) 248, 256
nalmefene 203
naloxone 203, 220
naltrexone 203, 223
National Comorbidity Survey 92
National Institute for Health and Care Excellence (NICE) 30, 112
National Psychiatric Morbidity Survey 92
NAVIGAGTE 22
nefazodone 52, 174
negative reinforcement 327, 328
negative reinforcers 330, 334
negative symptoms of schizophrenia 5, 17, 342
Netherlands Study of Depression and Anxiety 86
neurasthenic neurosis 85
neuroleptic medication 341
neuromodulator 336
neuropsychiatric symptoms (NPS) 300–307
neurovegetative symptoms of depression 92–93
nitrazepam 171
nocebo 49, 331, 337
nonadherence/noncompliance 69–70
nonpharmacologic intervention 9
nonresponders 45
nonsteroidal anti-inflammatory drug (NSAID) 203
norepinephrine 42, 110, 244	norepinephrine-dopamine reuptake inhibitor (NDRI) 97
nortriptyline 203
nucleus accumbens 330, 332
number needed to treat (NNT) 22, 286, 290
Nutritional education 7

O
obsessive-compulsive disorder (OCD) 118–121
off-label prescribing for children 245, 256
olanzapine 5, 72, 140, 260, 304
omega-3-polyunsaturated fatty acid 142, 203
ondansetron 223
One-trial learning 335
operant behavioral strategies 207
operant (instrumental) conditioning 325, 330, 332
operant reinforcers 332
opioids 8, 193, 333, 344
abuse 201, 204
analgesics 203
opioid-related fatalities 193, 203
sparing 202–204
oppositional defiant disorder (ODD) 251–258
child-focused individual and group interventions
problem-solving skills training (PSST) 254
anger control skills training (ACST) 254
parent training programs 252–254
Helping the Noncompliant Child (HNC) 253
Incredible Years (IY) training series 253
Parent-child interaction therapy (PCIT) 253
Parent Management Training Oregon Model (PMTO) 254
Triple P-Positive Parenting Program 253
OPUS trial 22
orexin/hypocretin antagonists 6, 173–174
Outreach and Support Intervention Services (OASIS) 28

P
pain 4, 304
acute pain 194, 195
back schools 206
chronic pain 6, 8, 193–216, 344–345
multidisciplinary pain clinic 194, 196
Pain Stages of Change Questionnaire 198
paliperidone 141
panic disorder 115–116
Parachute Project 28
paradoxical intention 176
paraphilia 347
paroxetine 44, 99, 222
patient expectation 39, 53–54
Patient Health Questionaire-9 (PHQ-9) 101
patient preference/choice 53, 181
patient variables 332
persistent depressive disorder 92
personality disorders clusters 90, 137
pharmacodynamics 96
pharmacotherapy with anxiety 109–110
generalized anxiety disorder (GAD) 110–111
obsessive-compulsive disorder (OCD) 119
panic disorder 115
posttraumatic stress disorder (PTSD) 117
social anxiety disorder 114
specific phobias 112
borderline personality disorder 138–143
childhood/adolescent disorders
attention deficit hyperactivity disorder (ADHD) 244–246
conduct disorder 259–262
oppositional defiant disorder (ODD) 251–252
eating disorders 219–224
pharmacotherapy with (continued)
elderly
behavioral disturbances concomitant
with dementia 304–306
cognitive deficits of
dementia 292–295
depression concomitant with
dementia 298
late-life depression 286–288
psychotic symptoms concomitant
with dementia 301–302
insomnia 169–177
mood disorders
adjustment disorder with
depression 95–98
bipolar disorder 74
depressive symptoms 71–72
dysthymic disorder 88–90
major depressive disorder 42–46
manic symptoms 66–67
pain 201–204
psychosis 31
phasic vs. tonic release 332–333
phenelzine 114
Pittsburgh Sleep Quality Index
(PSQI) 178
placebo 4, 49, 330, 331, 335, 336
meta-analyses 112, 171
response rate 171, 286, 288, 298
washout 91, 328
placebo-controlled trials 2, 44, 48, 89,
117
pleasure center 331–333, 336
polypharmacy 2, 9, 139, 174, 250
polysomnography 170
positive reinforce 330, 332
positive symptoms of schizophrenia
5, 18
posttraumatic stress disorder
(PTSD) 117, 118
prazosin 117, 305
pregabalin 109, 175
prescribing process 10
prefrontal lobe 244, 246
Premack principle 337, 340
primary care setting 51, 53–54, 95–96
chronic pain management 209
subacute pain management 208
problem-solving therapy (PST) 5, 7–8,
90, 99–100, 288, 291
probuphine 203
procrastination 341
prodromal symptoms 64
propranolol 115
psychoanalysis 2, 20, 47
psychodynamic therapy 2, 6, 46–47,
109, 111, 114–116, 143
psychoeducational component to
therapy 27, 63–65, 70
psychogenic pain 195
psychoses 4, 5, 17–37
psychosocial intervention
7–9
anxiety
generalized anxiety disorder
(GAD) 111
obsessive-compulsive disorder
(OCD) 119–120
panic disorder 116
posttraumatic stress disorder
(PTSD) 117
social anxiety disorder 114–115
specific phobias 112–113
borderline personality
disorder 143–153
childhood/adolescent disorders
attention deficit hyperactivity
disorder (ADHD) 246–248
conduct disorder 263–266
oppositional defiant disorder
(ODD) 252–255
eating disorders 224–226
elderly
behavioral disturbances concomitant
with dementia 306–307
cognitive deficits of
dementia 295–297
depression concomitant with
dementia 299–300
late-life depression 288–290
psychotic symptoms concomitant
with dementia 302–303
insomnia 176–179
mood disorders
adjustment disorder with
depression 98–100
bipolar disorder  72–74
major depressive disorder  47–49
pain  195–200, 204–209
psychosis  31
psychotic symptoms concomitant with dementia  300–303
psychostimulants  7, 9, 220, 223, 244, 257, 262, 332
psychotherapy  8

q
quality-of-life measures  50
quetiapine  5, 72, 140, 175, 332

r
RAISE Connection Program  28
ramelteon  172
randomization  53
randomized controlled trial (RCT)  1, 3, 20–25, 39, 48
rapid eye movement (REM) sleep  174, 175
reality-oriented therapy  295, 302
reboxetine  99, 268
reinforcement  325
reinforcer  330
relapse  8, 49, 65, 67, 76, 91, 116
relapse prevention  74–76
relaxation training  99, 115, 120, 177, 197
reminiscence and life review therapy  288
remission  51–53, 96, 116
renal monitoring  66
reserpine  42
resistant to treatment  118, 119, 120
respondent conditioners  334
respondent conditioning see classical (respondent) conditioning
response prevention  119, 339–340
reward  325
risk of overdose  109
risperidone  5, 117, 251, 260
ritanserin  89
rivastigmine  292–293, 336

s
schema-focused therapy (SFT)  146
schizoaffective disorder  18
schizophrenia  18
Schizophrenia Patient Outcomes Research Team (PORT)  30
schizoaffective disorder  18
schizotypal personality disorder  18
scientist-practitioner  90, 121
second-generation antipsychotic medication  5, 66
second-order conditioning  331
selective serotonin reuptake inhibitor (SSRI)  5–8, 42, 89, 97, 108, 219, 221, 305
self-selection  39 see also patient preference/choice
seligman differentiation  47
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)  52–53
sequenced treatment strategies  118, 180, 249
serotonin  42
serotonin-norepinephrine reuptake inhibitor (SNRI)  5, 7, 42, 97, 219, 221
sertraline  44, 91, 99
serum/blood level  66, 69, 87
severely underweight anorexics  219–220, 225
sexual disorders  346–347
shorter therapies for borderline personality disorder  151–152
sildenafil  346
side effects  43, 67, 115, 223
agranulocytosis  68
blood dyscrasia  141
side effects (continued)
- decreased appetite 245
- extrapyramidal side effects 140, 252, 301
- galactorrhea 141
- hypothyroidism 68
- increased blood pressure 246
- neuroleptic malignancy syndrome 260
- overdose, fatality 169, 172, 174, 194, 199, 256, 257, 293, 301
- prolonged Q-T interval 43, 68, 119, 302, 305
- sedation 222, 304
- seizure threshold 43, 222
- serotonin syndrome 43
- sexual 43
- Steven–Johnson syndrome 43, 68, 142
- suicide 43
- tardive dyskinesia 66, 143
- Torsades de Pointes 119
- weight change/metabolic syndrome 68, 222
- single-blind condition 50
- sleep disorder 4–5, 167–192
- sleep disturbance 96–97
- sleep hygiene 176
- sleep log 183
- sleep restriction 178
- slope regression analysis 52
- smelling salts 347
- Snoezelen therapy 307
- social anxiety 114–115
- social learning/modeling 328, 335, 347
- social rhythm therapy 63
- sodium amytal 118
- somatoform disorder 193–216
- specialized treatment early in psychosis (STEP) 21
- specific phobias 112–114
- Spielman, Arthur 168
- spiritual integrated psychotherapy (SIPT) 92
- state-dependent learning 113, 327
- State-Trait Anger Expression Inventory (STAXI) 142

stimulus control 177
- Stroop Color Word Test 288
- Structured Clinical Interview for DSM-IV (SCID) 95
- Subjective Unit of Distress (SUD) 124, 338
- Success Index (medication’s relative efficacy x tolerability) 98
- suicidality 5, 67, 72, 94–95, 100, 140, 152
- suicide 62, 69, 71, 118, 137
- sulpride 89
- supportive psychotherapy (SP) 91
- suvorexant 173
- switching (from depression to hypomania/mania) 5
- Symptom Checklist-90-Revised 141
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) 73
- Systemic family therapy 226
- Systems Training for Emotional Predictability and Problem Solving (STEPPS) 6, 145

<table>
<thead>
<tr>
<th>t</th>
</tr>
</thead>
<tbody>
<tr>
<td>tapendolol 203</td>
</tr>
<tr>
<td>tele-therapy 51, 64–65, 178</td>
</tr>
<tr>
<td>temazepam 179</td>
</tr>
<tr>
<td>thiothixene 139</td>
</tr>
<tr>
<td>thought disorder 8, 221</td>
</tr>
<tr>
<td>thyroid function 66</td>
</tr>
<tr>
<td>token economy 254, 265</td>
</tr>
<tr>
<td>topiramate 142, 219, 223</td>
</tr>
<tr>
<td>Toronto Alexithymia Scale 94</td>
</tr>
<tr>
<td>Trail Making Test 287</td>
</tr>
<tr>
<td>tramadol 193, 203</td>
</tr>
<tr>
<td>transference-focused psychotherapy (TFP) 146</td>
</tr>
<tr>
<td>tranylcypromine 139</td>
</tr>
<tr>
<td>trauma-focused psychotherapy 117</td>
</tr>
<tr>
<td>trauma-related nightmares 117</td>
</tr>
<tr>
<td>traumatic brain injury (TBI) 207</td>
</tr>
<tr>
<td>trazodone 174</td>
</tr>
<tr>
<td>treatment as usual (TAU) 21–25, 40, 144, 258</td>
</tr>
</tbody>
</table>
tricyclic antidepressant (TCA)  6, 42, 88, 115, 221
trifluoperazine  139
trimipramine  174
tyramine  43

U
unconditioned response (UCR)  329
unconditioned stimulus (UCS)  330, 331

V
valproate  5, 66, 251, 260–261
variables  2
(subject/patient)  3
vascular dementia  292, 294–295
vascular depression  285
venlafaxine  42, 45, 99
vicarious reinforcement  328
vilazodone  43, 222
vortioxetine  222

W
withdrawal symptoms/discontinuation syndrome  170, 201
worker’s compensation/disability insurance  197
World Federation of Societies of Biological Psychiatry (WFSBP)  119

Y
Yale–Brown Obsessive Compulsive Scale  119
yohimbine  110

Z
zaleplon  171
Z-drug  6, 171–172
ziprasidone  5
zolpidem  171
zonisamide  223
zopiclone  179